TRUFF (Rhelion Life Sciences) Ending Cash Position: $6.17 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rhelion Life Sciences Ending Cash Position?

Rhelion Life Sciences TRUFF -2.34% Ending Cash Position is $6.17 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Rhelion Life Sciences's Ending Cash Position for the quarter that ended in Mar. 2026 was $6.17 Mil.

Rhelion Life Sciences's quarterly Ending Cash Position declined from Sep. 2025 ($7.39 Mil) to Dec. 2025 ($6.70 Mil) and declined from Dec. 2025 ($6.70 Mil) to Mar. 2026 ($6.17 Mil).

Rhelion Life Sciences's annual Ending Cash Position declined from Mar. 2024 ($10.62 Mil) to Mar. 2025 ($8.94 Mil) and declined from Mar. 2025 ($8.94 Mil) to Mar. 2026 ($6.17 Mil).

Rhelion Life Sciences Ending Cash Position Related Terms

Rhelion Life Sciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Rhelion Life Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhelion Life Sciences Ending Cash Position Chart

Rhelion Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial 20.61 13.51 10.62 8.94 6.17

Rhelion Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.94 8.38 7.39 6.70 6.17

Rhelion Life Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Rhelion Life Sciences's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=9.357+-3.183
=6.17

Rhelion Life Sciences's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=6.732+-0.558
=6.17

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $6.17 Mil mean?
Rhelion Life Sciences (TRUFF) has a Ending Cash Position of $6.17 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Rhelion Life Sciences and its competitors.
Is Rhelion Life Sciences' Ending Cash Position too high?
Rhelion Life Sciences' current Ending Cash Position is $6.17 Mil.
How does Rhelion Life Sciences' Ending Cash Position compare to ZTS?
Rhelion Life Sciences' Ending Cash Position of $6.17 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Rhelion Life Sciences and its competitors. Rhelion Life Sciences's current Ending Cash Position is $6.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (TRUFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 4.5% above its estimated fair value. The current Ending Cash Position is $6.17 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Rhelion Life Sciences (TRUFF), the current Ending Cash Position is $6.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhelion Life Sciences Business Description

Other Exchanges 4YX:GermanyTRIP:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.